Member Info for Bella6532

From Dec 2023...

https://www.fiercebiotech.com/biotech/how-novartis-readout-causing-trouble-eli-lillys-14b-radiotherapy-buy

Check out their position on ADCs...

https://www.fiercepharma.com/pharma/jpm24-cancer-players-jump-head-first-adc-field-novartis-ceo-explains-how-hes-resisted

Now I do think they are one to watch...Munro has made nice comments re Avacta trial on X and she obviously knows CC.

'pre|CISIONTM ADC

The Avacta pre|CISION-ADC platform leverages the FAP-activated tumour-specific release mechanism of the pre|CISIONTM technology with the tumour-targeting capability of an antibody or Affimer®.

The mechanism of action of the pre|CISION-ADC model optimises warhead delivery by targeting the warhead to the TME in two ways: with the antibody or Affimer® target and FAP-release in the TME.

Optimisation of the bystander effect is a key benefit of the mechanism of the pre|CISION-ADC platform. The biologic targets the molecule to the TME through a non-internalising mechanism and membrane-bound FAP releases the warhead in the extracellular space, thus equally targeting both antigen-positive and antigen-negative tumour cells.

The dual-delivery by a pre|CISION-ADC drug leveraging both a tumour antigen to target and FAP to release the warhead will significantly reduce the off-tumour toxicities associated with traditional ADC mechanisms'

SIGNIFICANTLY REDUCE THE OFF-TUMOUR TOXICITIES ASSOCIATED WITH TRADITIONAL ADC MECHANISMS.

As I said earlier..roll up Big Pharma and come and get your ADCs wrapped in our beautiful PreCision wrapper...just sign the dotted line and we'll get working on it right away for you and here's our bank details.

All you big pharmas now just need to wrap your newly acquired ADC drugs in a nice little PreCision wrapper...just contact Avacta and a licencing deal can be yours for a cut of the action. Bingo and all those nasty ADC side effects will be history.

The presentation will include updated data from the Phase 1 trial beyond those included in the abstract. A copy of the abstract will be available on Avacta’s website at: https://avacta.com/about/scientific-resources/.

Copies of the poster will be available on Avacta's website following the conference at: https://avacta.com/about/resources/posters/.

Christina Coughlin will provide a video presentation overview examining the data presented in the poster. This will be available on 10th April at https://avacta.com/investors/documents-presentations/.

Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data. Registration for the event is via the following link:

https://www.turnerpope.com/register/

From abstract conclusion...

'AVA6000 delivers high concentration of doxorubicin to the TME relative to plasma which results in antitumor activity in tumors with high FAP activity.'

'WHICH RESULTS IN ANTITUMOR ACTIVITY...'

'Internal

pre|CISION™ AVA6000 – FAPα activated doxorubicin

Phase 1

pre|CISION™ AVA3996 – FAPα activated proteasome inhibitor

Pre Clinical

AVA028 / 032 – PD-L1 Affimer® / ImmunoCytokines

Research

AVA021 – PD-L1 Affimer® / LAG-3 Affimer®

Research

TMAC® platform

Research

Undisclosed targets

Research

Partnered

LR19128 PD-L1 XT®

Pre Clinical

Undisclosed targets

Research

AFX-001 Solid Organ Transplant

Pre Clinical

AFX-001 Graft vs Host Disease

Pre Clinical

AFX-002 Multiple Sclerosis

Research

CLOSE

TMAC® platform

TMAC® utilises the proprietary pre|CISION™ substrate to provide for the selective release of a drug moiety by FAPα. These FAP-activated Affimer® drug conjugates are designed to release drug moieties in the extracellular space of the tumour, rather than inside the tumour cell as is the case with traditional antibody-drug conjugates (ADCs). This novel class of drug conjugates is terms “tumour microenvironment activated drug conjugates” or TMACs. In the TMAC® format, Avacta can deliver otherwise acutely toxic immune activating molecules, which circulate in an inert form as the conjugate but which release potent activators of innate immunity when the linker is cleaved by FAPα in the tumour and the Affimer® also provides adaptive immune therapeutic activity.'

Peptide Drug Conjugates – Multiple advantages over traditional ADC

See full details on the new Avacta website...

They certainly are going for it...

Let's see how it looks by Sunday/Monday...I suspect it's a rush job update and they still have to download DX back onto site.

And pre|CISIONTM antibody/Affimer® drug conjugates …”....TMAC ???

But TMAC is not in Glossary List..???

Either sold or updates are a co*k up and they forgot to add the DX pages back in or Avacta is making DX a stand alone subsidiary. RNS Monday.

Again..stop squabling like a bunch of school kids and submit your question(s)...I've submitted mine and yes I've posed several questions which are all inter-linked. Move on with your lives for heavens sake...it's far too short...and precious...

05-Apr-24 08:19:18 50.50 100,000 Buy* 50.50k O

05-Apr-24 08:19:09 50.00 100,000 Unknown* 50.00k

So where does the 5 more months come into play or was she simply stating he will be dosed as needed up to the end of 1a trial.

If he was scheduled to get 12 doses max each 3 weeks apart that's 36 weeks in total or 9 months. So if he had 5 months to go in Dec then he was probably first dosed in August. Now, if he was on full dose (3x normal dox dose) what has been observed since December? If the Dox is going straight to the tumour(s) and doing what Dox should do...kill cancer cells...and if PreCision is still able to protect further damage to his other vital organs etc...has it distroyed the tumour(s) altogether by now. Is this what we will hear about next week??? If so and he's in remission then that's basically a cure.

So...all these Phamas investing in ADCs need to get their drugs a 'does what it says on the tin' PreCision warhead to reduce the side effects and increase the dose to tumour ration...mmmm! Bring on the next PreCision candidates...

Novartis is one of the main backers of Medicxi funds...

I would still like Medicxi to be our unnamed European Fund investor...

Genmab is on the Medicxi list of companies.

https://www.medicxi.com/companies/genmab-cph-gen

Don't forget the 2 x 250K on Thurs.

Anyone done the maths for the new HCI price yet...

Yep order filled...and that's why they were sent here to bla bla bla...